No Detail Found!

Role of Oral Rifampicin in Chronic Central Serous Chorioretinopathy.

Author(s)
P.S. Mahar Isra Postgraduate Institute of Ophthalmology Karachi, Pakistan
Nasir Memon Isra Postgraduate Institute of Ophthalmology Karachi, Pakistan
A. Sami Memon Isra Postgraduate Institute of Ophthalmology Karachi, Pakistan
M. Faisal Faheem Isra Postgraduate Institute of Ophthalmology Karachi, Pakistan
Abstract
Purpose: To determine the improvement in visual acuity and central macular thickness in patients with chronic central serous chorioretinopathy (CSCR) with oral Rifampicin. Study Design: Quasi experimental study. Place and Duration of Study: Isra Postgraduate Institute of Ophthalmology, Al-Ibrahim Eye Hospital, Karachi. From September 2015 to December 2016. Material & Methods: Ten eyes of 10 patients having chronic CSCR of more than 6 months duration were prospectively treated with oral Rifampicin 450 mg in single oral dose for 3 months duration. All patients were followed-up for 12 months. Results: Ten eyes of 10 patients were included in the study. The gender distribution showed 8 male (80%) and 2 female (20%) patients. There were five right and five left eyes. Mean age of our patients was 40.10 ± 5.1 years (Range 34 - 46 years). Mean duration of patient’s ocular symptoms was 9.4 ± 2.9 months with range of 6 - 14 months. Patient’s visual acuity improved at 3 months follow-up. Mean Pre-treatment central macular thickness was 350 ± 82.3 µm improving to 232 ± 54.3 µm at 3 months treatment. Conclusion: All patients with chronic CSCR of more than 6 months duration showed improvement in their vision and central macular thickness with oral Rifampicin taken for 3 months.
Publication Details
Page(s) 3-8
DOI DOI not available
Published Journal: Pakistan Journal of Ophthalmology , Volume: 34, Issue: 1, Year: 2018

Request the full text from PASTIC

0

Citations

0

Downloads

27

Views